Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyethylene glycol loxenatide
- Development stage
- Phase 4
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Polyethylene glycol loxenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for the treatment of type 2 diabetes mellitus. It is derived from exendin-4 and modified with polyethylene glycol (PEG) to enhance its pharmacokinetic properties. This modification increases its half-life and reduces immunogenicity, allowing for once-weekly administration. It is also being explored for its potential effects on weight management and cardiovascular outcomes.
- Brand names
- Peganlin
- Other names
- PEG loxenatidePEG-LoxenatidePolyethylene glycol (PEG) loxenatideFulaimei
02
Targets
Beyond the preview
Go deeper on polyethylene glycol loxenatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyethylene glycol loxenatide.